Brief: UK's MHRA Approves Rilzabrutinib To Treat Adults With Immune Thrombocytopenia
29/05/2026 12:31
BRIEF-UK's MHRA Approves Rilzabrutinib To Treat Adults With Immune Thrombocytopenia May 29 (Reuters) - UK's MHRA:
UK'S MHRA: RILZABRUTINIB AUTHORISED TO TREAT ADULTS WITH IMMUNE THROMBOCYTOPENIA WHEN PRIOR TREATMENTS HAVE BEEN INSUFFICIENT
Further company coverage: SASY.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sanofi SA
See all newsEdenTree fund manager Hiorns has bought up French stocks despite civil unrest (updated)
Early US flu season, current strain may signal risk for younger people; doctors urge shots
Brief: Sanofi Starts Work On Insulin Facility In Germany
RCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Europe Research Roundup: AJ Bell, CMC Markets, Nestle